A targeted proteomics approach for biomarker discovery using bilateral matched nipple aspiration fluids

Jinong Li, Junma Zhou, Bruce Trock, Theodore N. Tsangaris, Neil B. Friedman, Deanna Shapiro, Michelle Brotzman, Daniel Wan-Yui Chan

Research output: Contribution to journalArticle

Abstract

Introduction: The objective of this study was to identify cancer-associated protein expression patterns in bilateral matched nipple aspiration fluids using nanoscale reciprocal Cy3/Cy5 labeling and high-content antibody microarrays. This novel platform allows the pair-wise comparisons of the relative abundance of 512 different antigens using minimal NAF sample containing 1 μg of total protein. Material and Methods: Matched NAF samples from two normal controls and 18 patients with early stage breast cancer (stage I/II, 13; DCIS, 2) or precancerous lesions (ADH, 3) were studied. Self-to-self and left-to-right comparisons of the normal controls were performed to determine antigen variations due to normal experimental and biological variability. Based on these two experiments, a stringency filter of 15% was applied to eliminate noise. Antigens were considered differentially expressed if there were a consistent >15% change on relative Cy3/Cy5 signals on reciprocal slides. Results and Discussion: The number of differentially expressed antigens varied between 10 and 72 in tumor associated NAF samples, and no single antigen can be used as a "universal" marker to identify all patients. Antigens that are elevated in at least four patients were selected for further evaluations, including NME1, PTK2B, ARRB1, MRIP, GFRA1, APC, HSPD1, and SLP76. The validity of the antibody array findings was affirmed by single immunoassay on western blot; elevated expression of four of the selected markers in NAF is supported by published immunohistochemistry studies on breast cancer tissues. Conclusions: Nipple aspiration fluid is a rich source of breast cancer biomarkers. This targeted proteomics approach for biomarker discovery is proven effective for clinical samples with limited protein content.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalClinical Proteomics
Volume6
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Nipples
Biomarkers
Proteomics
Antigens
Fluids
Breast Neoplasms
Antigenic Variation
Proteins
Carcinoma, Intraductal, Noninfiltrating
Antibodies
Tumor Biomarkers
Immunoassay
Noise
Microarrays
Neoplasms
Labeling
Western Blotting
Immunohistochemistry
Tumors
Tissue

Keywords

  • Antibody microarray
  • Biomarker
  • Breast cancer
  • Nipple aspiration fluid
  • Proteomicsz

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Clinical Biochemistry

Cite this

A targeted proteomics approach for biomarker discovery using bilateral matched nipple aspiration fluids. / Li, Jinong; Zhou, Junma; Trock, Bruce; Tsangaris, Theodore N.; Friedman, Neil B.; Shapiro, Deanna; Brotzman, Michelle; Chan, Daniel Wan-Yui.

In: Clinical Proteomics, Vol. 6, No. 3, 09.2010, p. 57-64.

Research output: Contribution to journalArticle

Li, Jinong ; Zhou, Junma ; Trock, Bruce ; Tsangaris, Theodore N. ; Friedman, Neil B. ; Shapiro, Deanna ; Brotzman, Michelle ; Chan, Daniel Wan-Yui. / A targeted proteomics approach for biomarker discovery using bilateral matched nipple aspiration fluids. In: Clinical Proteomics. 2010 ; Vol. 6, No. 3. pp. 57-64.
@article{de23dc80ef674c35be4f3d8448f4ec8b,
title = "A targeted proteomics approach for biomarker discovery using bilateral matched nipple aspiration fluids",
abstract = "Introduction: The objective of this study was to identify cancer-associated protein expression patterns in bilateral matched nipple aspiration fluids using nanoscale reciprocal Cy3/Cy5 labeling and high-content antibody microarrays. This novel platform allows the pair-wise comparisons of the relative abundance of 512 different antigens using minimal NAF sample containing 1 μg of total protein. Material and Methods: Matched NAF samples from two normal controls and 18 patients with early stage breast cancer (stage I/II, 13; DCIS, 2) or precancerous lesions (ADH, 3) were studied. Self-to-self and left-to-right comparisons of the normal controls were performed to determine antigen variations due to normal experimental and biological variability. Based on these two experiments, a stringency filter of 15{\%} was applied to eliminate noise. Antigens were considered differentially expressed if there were a consistent >15{\%} change on relative Cy3/Cy5 signals on reciprocal slides. Results and Discussion: The number of differentially expressed antigens varied between 10 and 72 in tumor associated NAF samples, and no single antigen can be used as a {"}universal{"} marker to identify all patients. Antigens that are elevated in at least four patients were selected for further evaluations, including NME1, PTK2B, ARRB1, MRIP, GFRA1, APC, HSPD1, and SLP76. The validity of the antibody array findings was affirmed by single immunoassay on western blot; elevated expression of four of the selected markers in NAF is supported by published immunohistochemistry studies on breast cancer tissues. Conclusions: Nipple aspiration fluid is a rich source of breast cancer biomarkers. This targeted proteomics approach for biomarker discovery is proven effective for clinical samples with limited protein content.",
keywords = "Antibody microarray, Biomarker, Breast cancer, Nipple aspiration fluid, Proteomicsz",
author = "Jinong Li and Junma Zhou and Bruce Trock and Tsangaris, {Theodore N.} and Friedman, {Neil B.} and Deanna Shapiro and Michelle Brotzman and Chan, {Daniel Wan-Yui}",
year = "2010",
month = "9",
doi = "10.1007/s12014-010-9046-z",
language = "English (US)",
volume = "6",
pages = "57--64",
journal = "Clinical Proteomics",
issn = "1542-6416",
publisher = "BioMed Central",
number = "3",

}

TY - JOUR

T1 - A targeted proteomics approach for biomarker discovery using bilateral matched nipple aspiration fluids

AU - Li, Jinong

AU - Zhou, Junma

AU - Trock, Bruce

AU - Tsangaris, Theodore N.

AU - Friedman, Neil B.

AU - Shapiro, Deanna

AU - Brotzman, Michelle

AU - Chan, Daniel Wan-Yui

PY - 2010/9

Y1 - 2010/9

N2 - Introduction: The objective of this study was to identify cancer-associated protein expression patterns in bilateral matched nipple aspiration fluids using nanoscale reciprocal Cy3/Cy5 labeling and high-content antibody microarrays. This novel platform allows the pair-wise comparisons of the relative abundance of 512 different antigens using minimal NAF sample containing 1 μg of total protein. Material and Methods: Matched NAF samples from two normal controls and 18 patients with early stage breast cancer (stage I/II, 13; DCIS, 2) or precancerous lesions (ADH, 3) were studied. Self-to-self and left-to-right comparisons of the normal controls were performed to determine antigen variations due to normal experimental and biological variability. Based on these two experiments, a stringency filter of 15% was applied to eliminate noise. Antigens were considered differentially expressed if there were a consistent >15% change on relative Cy3/Cy5 signals on reciprocal slides. Results and Discussion: The number of differentially expressed antigens varied between 10 and 72 in tumor associated NAF samples, and no single antigen can be used as a "universal" marker to identify all patients. Antigens that are elevated in at least four patients were selected for further evaluations, including NME1, PTK2B, ARRB1, MRIP, GFRA1, APC, HSPD1, and SLP76. The validity of the antibody array findings was affirmed by single immunoassay on western blot; elevated expression of four of the selected markers in NAF is supported by published immunohistochemistry studies on breast cancer tissues. Conclusions: Nipple aspiration fluid is a rich source of breast cancer biomarkers. This targeted proteomics approach for biomarker discovery is proven effective for clinical samples with limited protein content.

AB - Introduction: The objective of this study was to identify cancer-associated protein expression patterns in bilateral matched nipple aspiration fluids using nanoscale reciprocal Cy3/Cy5 labeling and high-content antibody microarrays. This novel platform allows the pair-wise comparisons of the relative abundance of 512 different antigens using minimal NAF sample containing 1 μg of total protein. Material and Methods: Matched NAF samples from two normal controls and 18 patients with early stage breast cancer (stage I/II, 13; DCIS, 2) or precancerous lesions (ADH, 3) were studied. Self-to-self and left-to-right comparisons of the normal controls were performed to determine antigen variations due to normal experimental and biological variability. Based on these two experiments, a stringency filter of 15% was applied to eliminate noise. Antigens were considered differentially expressed if there were a consistent >15% change on relative Cy3/Cy5 signals on reciprocal slides. Results and Discussion: The number of differentially expressed antigens varied between 10 and 72 in tumor associated NAF samples, and no single antigen can be used as a "universal" marker to identify all patients. Antigens that are elevated in at least four patients were selected for further evaluations, including NME1, PTK2B, ARRB1, MRIP, GFRA1, APC, HSPD1, and SLP76. The validity of the antibody array findings was affirmed by single immunoassay on western blot; elevated expression of four of the selected markers in NAF is supported by published immunohistochemistry studies on breast cancer tissues. Conclusions: Nipple aspiration fluid is a rich source of breast cancer biomarkers. This targeted proteomics approach for biomarker discovery is proven effective for clinical samples with limited protein content.

KW - Antibody microarray

KW - Biomarker

KW - Breast cancer

KW - Nipple aspiration fluid

KW - Proteomicsz

UR - http://www.scopus.com/inward/record.url?scp=77956652277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956652277&partnerID=8YFLogxK

U2 - 10.1007/s12014-010-9046-z

DO - 10.1007/s12014-010-9046-z

M3 - Article

AN - SCOPUS:77956652277

VL - 6

SP - 57

EP - 64

JO - Clinical Proteomics

JF - Clinical Proteomics

SN - 1542-6416

IS - 3

ER -